The confirmed drug-target interactions suggest an attenuation of pulmonary vascular remodeling (inhibition of PDE10A), modulation of Hepatitis C (HCV) viral response (inhibition of PKN2), and hypomagnesemia (inhibition of TRPM6). The gene discussed is PKN2; the disease is familial primary hypomagnesemia.